688089 Cabio Biotech(Wuhan)
- 25.10
- +4.18+19.98%
Cabio Biotech(Wuhan) News
Resumed trading with a one-character limit up, cabio biotech(wuhan) intends to acquire 65% equity of Eurobio symbol company with high debts.
1. Eurobio achieved a turnaround in profitability starting in 2023. From the first three quarters of 2022 to 2024, the target company achieved revenues of 0.265 billion yuan, 0.309 billion yuan, and 0.267 billion yuan respectively; 2. Xinda Securities stated that considering the closely related multiple group testing of the target company with cabio biotech(wuhan)'s existing synthetic biology research and development, it is expected that the two will form a strong synergistic effect.
Cabio Biotech(Wuhan) (688089.SH): intends to acquire 65.00% equity of EU Bio from November 12 and will resume trading.
On November 11th, Cabio Biotech (wuhan) (688089.SH) announced that the company plans to purchase 65.00% equity of Ouyi Biotech from 14 trading partners including Wang Shuwei, Dong Dong, Xiao Yunping, Wang Xiuping, Jin Chao, Shi Xianjun, Shanghai Fanyi, Ningbo Ruio, Ningbo Ouren, National Pharmaceutical Phase II, Nantong Dongzheng, Suzhou Dingshi, Shanghai Biology, Shanghai Shengqi, through the issuance of shares and cash payment, and raise supporting funds. The final transaction price of the target assets will be based on the evaluation results of the evaluation report issued by the asset evaluation institution in accordance with the Securities Law, and will be determined through full negotiation between the two parties. The target company consists of multiple
Cabio Biotech (Wuhan) (688089.SH) is planning a major asset restructuring, and the stocks will continue to be suspended from trading.
cabio biotech(wuhan) (688089.SH) announced that the company is planning to purchase shanghai through the issuance of shares and payment of cash...
Cabio Biotech(Wuhan) (688089): Q3 profits under short-term pressure, planning assets restructuring.
Event: The company released the third quarter report for 2024. In 2024 Q1-3, the company achieved revenue of 0.387 billion yuan, a year-on-year increase of +19.19%; net income attributable to the parent company was 83.89 million yuan, a year-on-year increase of +38.86%; after-tax net income attributable to the parent company
Express News | Three mergers in a single day! The merger and reorganization market remains active, showing four major new trends.
cabio biotech(wuhan) (688089): Seize the opportunity of layout and plan to acquire equity of Europe easy.
Announcement of the company's 2024 third quarter report. In the first three quarters of 2024, the company achieved a total revenue of 0.387 billion yuan (+19.19%), a net profit attributable to the parent company of 0.084 billion yuan (+38.86%), and a non-GAAP net profit of 0.
Cabio Biotech(Wuhan)(688089): Revenue structure leads to pressure on gross margin, planning to acquire Ouli Biotech.
Executive summary of this report: In Q3 24, the company's revenue increased by 0.2% year-on-year, while profits declined, mainly due to concentrated overseas purchases in Q2 and a decrease in the proportion of overseas revenue in Q3. The company announced plans to issue shares to acquire Ouyi Biotech, expanding its layout in the biotechnology sector.
Jia Biyou: Jia Biyou Biotechnology (Wuhan) Co., Ltd. Report for the third quarter of 2024
Jiabiyou Biotechnology (Wuhan) Co., Ltd. Report for the third quarter of 2024
Cabio Biotech(Wuhan): Planning to acquire the controlling stake of Ouyi, stocks suspended from trading.
GeLongHui October 28th | Cabio Biotech (Wuhan) announcement, the company is planning to acquire the controlling stake of Euroeasy by issuing shares and paying cash, while also planning to raise matching funds. According to preliminary calculations, this transaction is expected to constitute a major asset restructuring. Following the company's application to the Shanghai Stock Exchange, the company's stocks will be suspended from trading starting on October 29, 2024 (Tuesday), with an expected suspension period not exceeding 5 trading days.
Express News | Cabio Biotech (Wuhan): Intends to issue shares and pay cash to acquire 65% equity of EuroE Stocks will be suspended from trading starting tomorrow.
Express News | Cabio Biotech (Wuhan) announced that the company is planning to acquire the controlling rights of Shanghai Ouyi Biomedical Technology Co., Ltd. (hereinafter referred to as "Ouyi" or "the target of the transaction") by issuing shares and paying cash, while
Cabio Biotech(Wuhan) (688089.SH) released its performance for the first three quarters, with a net income of 83.8902 million yuan, a year-on-year increase of 38.86%.
Cabio Biotech (688089.SH) released the report for the first three quarters of 2024, during the reporting period, the company achieved a revenue of 3...
cabio biotech(wuhan) (688089.SH): has not repurchased company shares.
On October 9, Gelonhui announced that, as of September 30, 2024, Cabio Biotech(Wuhan) (688089.SH) has not repurchased any shares of the company through the dedicated securities account for repurchase.
Cabio Biotech(Wuhan) (688089): Performance meets expectations, overseas growth rate shines.
This report summary: The performance of the company in the first half of 24H1 has shown high growth, in line with expectations, with a bright increase in overseas revenue. The company has benefited from the surge in international major customer orders, the new national standard, and the transition of domestic major customer production capacity, resulting in both revenue growth and improved profitability. Investment highlights: Investment advice:
Jiabiyou Biotechnology (Wuhan) Co., Ltd. 2024 Semi-Annual Report
Summary of the 2024 semi-annual report of Jiabiyou Biotechnology (Wuhan) Co., Ltd.
Cabio Biotech(Wuhan) (688089.SH): net income of 67.889 million yuan in the first half of the year, a year-on-year increase of 94.82%.
格隆汇August 27th丨Cabio Biotech (Wuhan) (688089.SH) announced its semi-annual report, with revenue of 0.26 billion yuan, a year-on-year increase of 31.23%, net income of 67.889 million yuan, a year-on-year increase of 94.82%, non-net profit of 53.007 million yuan, a year-on-year increase of 132.57%, and basic earnings per share of 0.40 yuan.
Cabio Biotech (688089.SH) released its semi-annual performance with a net income of 67.889 million yuan, a year-on-year increase of 94.82%.
Cabio Biotech (688089.SH) disclosed its semi-annual report for 2024, with the company realizing revenue of 2... in the reporting period.
Express News | Cabio Biotech(Wuhan): Intends to repurchase shares with 15 million to 30 million yuan.
Analysis
Price Target
No Data
No Data